Phase 2 IND submission targeted for the second half of 2026- Demonstrating the competitiveness of GC Biopharma's mRNA platform YONGIN, South Korea, Dec. 22, 2025 /PRNewswire/ -- GC Biopharma (006280 ...
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA
SINGAPORE, Oct. 26, 2023 /PRNewswire/ --On October 26, 2023, Biosyngen's TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA. BST02, a breakthrough product in ...
BOSTON--(BUSINESS WIRE)--Signet Therapeutics, a biotech company using organoid disease models and AI to advance targeted cancer therapy, today announced that the FDA has granted its IND application ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that the ...
JEIL PHARMACEUTICAL said on the 17th that its subsidiary Onconic Therapeutics received approval from the Ministery of Food and Drug Safety for an investigational new drug (IND) application for phase ...
CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially ...
The Food and Drug Administration (FDA) development and approval process for drugs and medical devices involves multiple phases that ensure the safety and effectiveness of products before and after ...
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development ...
YONGIN, South Korea, Dec. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, announced today that Ministry of Food and Drug Safety (MFDS) in South Korea has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback